<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39387432</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2791-6421</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>The Turkish journal of pediatrics</Title><ISOAbbreviation>Turk J Pediatr</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of COVID-19 vaccines in children and adolescents with cancer.</ArticleTitle><Pagination><StartPage>412</StartPage><EndPage>420</EndPage><MedlinePgn>412-420</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24953/turkjpediatr.2024.4512</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Children with cancer have a higher morbidity and mortality due to COVID-19. Vaccination of children with cancer is important. In this study, we aimed to investigate the effectiveness and side effects of the COVID-19 vaccines in children and adolescents with cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-eight patients from four centers were included in the study. Antibodies to the SARS-CoV-2 spike protein levels were measured. Vaccine-related complaints were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 33 male and 25 female patients. The mean age was 16.9±2.3 years. In 58.6% of cases, the diagnosis was hematological malignancies. Twenty patients were currently under treatment, while 38 had completed the treatment. Forty-eight patients received chemotherapy ± radiotherapy, 13 received immunotherapy, and 3 underwent stem cell transplantation. CoronoVac© and BNT162b2© vaccines were administered in 24% and 76%, respectively. The mean antibody level was lower in patients who received CoronaVac© than that of BNT162b2©, although the difference was not significant. The levels were within the protective limits in both groups. No significant difference was found in antibody levels according to diagnostic subgroups, treatment status, type of treatment, line of treatment, disease status and time between vaccines and measurement of antibody level. The most common side effects were pain at the injection site (37.9%) and malaise/weakness (17.2%), which were similar for both vaccines.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study showed that both mRNA and inactivated vaccines elicit an immune response in children with cancer. However, the seroconversion rate is significantly higher in mRNA vaccines. Side effects were similar to those seen in healthy children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurucu</LastName><ForeName>Nilgün</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Faculty of Medicine and Institute of Cancer, Hacettepe University, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutluk</LastName><ForeName>Tezer</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Faculty of Medicine and Institute of Cancer, Hacettepe University, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kartal</LastName><ForeName>İbrahim</ForeName><Initials>İ</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeşil</LastName><ForeName>Şule</ForeName><Initials>Ş</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Ankara Dr. Sami Ulus Training and Research Hospital, Univeristy of Health Sciences, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vural</LastName><ForeName>Özge</ForeName><Initials>Ö</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Faculty of Medicine, Gazi University, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinçer</LastName><ForeName>Oğuz S</ForeName><Initials>OS</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceyhan</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatric Infectious Disease, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk J Pediatr</MedlineTA><NlmUniqueID>0417505</NlmUniqueID><ISSNLinking>0041-4301</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">immunization</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>21</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>21</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>7</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39387432</ArticleId><ArticleId IdType="doi">10.24953/turkjpediatr.2024.4512</ArticleId><ArticleId IdType="pii">4512</ArticleId></ArticleIdList></PubmedData></PubmedArticle>